Increasing Aripiprazole from 5mg to 10mg in a Patient Previously Tolerating Brexpiprazole
Increase aripiprazole directly from 5mg to 10mg as a single dose adjustment, without gradual titration, since the patient previously tolerated brexpiprazole (which shares similar D2 partial agonist properties) and 10mg is the established therapeutic target dose for aripiprazole.
Rationale for Direct Dose Increase
The FDA label for aripiprazole clearly states that the recommended starting and target dose is 10 or 15 mg/day, with dosage increases generally not made before 2 weeks (the time needed to achieve steady-state) 1. Since your patient is already on 5mg and has demonstrated tolerability of a structurally related D2 partial agonist (brexpiprazole), the 2-week waiting period has effectively been satisfied.
Key Supporting Evidence:
Aripiprazole 10mg is the optimal therapeutic dose: Multiple fixed-dose studies demonstrate that 10mg/day provides the highest response rates in schizophrenia, with doses above 20mg offering no additional benefit and potentially smaller symptom improvements 2, 3
Cross-tolerance from brexpiprazole: Brexpiprazole and aripiprazole share nearly identical receptor profiles as D2 partial agonists 4. Your patient's tolerance of brexpiprazole strongly predicts tolerance of aripiprazole 10mg, as both medications work through the same primary mechanism
No evidence supporting gradual titration from 5mg to 10mg: The FDA label and clinical trials show aripiprazole can be initiated at 10mg directly 1. The 5mg dose was not shown to be superior to placebo in acute schizophrenia trials 2
Practical Implementation
Simply increase to 10mg once daily immediately. The patient can take the new dose starting tomorrow without cross-titration or bridging strategies.
Timeline Expectations:
- Steady-state: Will be achieved in approximately 14 days due to aripiprazole's long half-life (75 hours for aripiprazole, 94 hours for active metabolite) 5
- Full therapeutic effect: May take 1-4 weeks to manifest 5
- Monitor closely during weeks 2-4 for both efficacy and tolerability
Important Caveats
Check for CYP450 Drug Interactions:
If your patient is taking:
- Strong CYP2D6 or CYP3A4 inhibitors (quinidine, fluoxetine, paroxetine, itraconazole, clarithromycin): Reduce target dose to 5mg (half the usual dose) 1
- Strong CYP3A4 inducers (carbamazepine, rifampin): May need to double the dose to 20mg over 1-2 weeks 1
- Known CYP2D6 poor metabolizers: Target dose should be 5mg, not 10mg 1
Monitor for Side Effects:
While the patient tolerated brexpiprazole, aripiprazole at 10mg may cause:
- Akathisia (most common limiting side effect)
- Activation/restlessness
- Insomnia
- Nausea (usually transient)
These are generally less severe than with higher D2 antagonist antipsychotics, but the partial agonist profile can cause subjective activation in some patients.
When NOT to Increase:
Do not increase if the patient is experiencing:
- Current akathisia or significant restlessness on 5mg
- Adequate symptom control at 5mg (though this is unlikely given 5mg showed no superiority to placebo in trials 2)
Alternative Consideration
If you're concerned about tolerability despite brexpiprazole history, you could increase to 7.5mg for one week as a brief intermediate step, though this lacks evidence-based support and delays reaching therapeutic dosing. The more evidence-based approach is direct increase to 10mg 1, 3.